Core Viewpoint - The report from Kaiyuan Securities highlights that CSPC Pharmaceutical Group (01093) is intensifying its focus on innovation, establishing eight major technology platforms, and has over 130 projects in its pipeline, indicating that the value of its innovations is entering a concentrated realization phase [1] Financial Projections - The company is expected to achieve net profit attributable to shareholders of 4.915 billion, 5.272 billion, and 5.714 billion yuan for the years 2025 to 2027, respectively [1] - Earnings per share (EPS) are projected to be 0.4, 0.5, and 0.5 yuan for the same years, with corresponding price-to-earnings (PE) ratios of 21.4, 20.0, and 18.4 times [1] Innovation and Collaborations - CSPC has recently entered into multiple external licensing agreements for several innovative products, including Lp(a), MAT2A, ROR1 ADC, and irinotecan liposome, with expected revenue recognition from these licenses in 2025 [1] - The company is actively negotiating licensing agreements for various innovative drug projects with international pharmaceutical companies, including a collaboration with AstraZeneca in June to develop a new oral small molecule candidate driven by AI [1] - In July, CSPC announced the global licensing of its small molecule GLP-1 receptor agonist SYH2086 to Madrigal Pharmaceuticals, which includes a $120 million upfront payment [1] - The realization of revenue from multiple pipelines is anticipated to become a second growth curve for the company [1]

Key Points - The article highlights the net inflow and outflow of funds for various companies in the Hong Kong market, with Alibaba-W leading the inflow [1][2] - It provides detailed statistics on the top companies with the highest net inflows and outflows, indicating market trends [2][3] Group 1: Net Inflows - Alibaba-W (09988) recorded a net inflow of 5.042 billion, representing a 20.09% increase in its closing price to 161.600 [2] - Meituan-W (03690) saw a net inflow of 2.098 billion, with a 14.37% increase in its closing price to 105.200 [2] - Changfei Optical Fiber (06869) had a net inflow of 0.989 billion, with an 18.51% increase in its closing price to 54.150 [2] Group 2: Net Outflows - Xiaomi Group-W (01810) experienced the highest net outflow of -0.644 billion, with a -6.48% change in its closing price to 57.850 [2] - China Mobile (00941) had a net outflow of -0.514 billion, reflecting a -25.37% decrease in its closing price to 86.600 [2] - Stone Pharmaceutical Group (01093) faced a net outflow of -0.415 billion, with an -18.51% change in its closing price to 10.010 [2] Group 3: Net Inflow Ratios - The top net inflow ratio was recorded by Standard Chartered Hong Kong 100 (02825) at 100.00%, with a net inflow of 0.0187 million [3] - Datang New Energy (01798) had a net inflow ratio of 53.77%, with a net inflow of 0.03897 million [3] - Jiangsu Ninghu Highway (00177) reported a net inflow ratio of 53.56%, with a net inflow of 0.02301 million [3] Group 4: Net Outflow Ratios - China National Heavy Duty Truck Group (03808) had the highest net outflow ratio at -66.74%, with a net outflow of -0.06031 billion [3] - Q Technology (01478) recorded a net outflow ratio of -51.13%, with a net outflow of -0.03931 billion [3] - China State Construction International (03311) faced a net outflow ratio of -44.37%, with a net outflow of -0.05668 billion [3]

Investment Rating - The report maintains an investment rating of "Outperform the Market" [5] Core Insights - The new drug sector has shown significant movements, with notable increases in stock prices for companies such as Kintor Pharmaceutical, which recently went public in Hong Kong, focusing on unmet clinical needs in oncology and immunology [2][3][21] - The KRAS G12D inhibitor GFH375 from Kintor Pharmaceutical has demonstrated promising clinical data in treating pancreatic cancer and non-small cell lung cancer (NSCLC), with an overall response rate (ORR) of 52% in pancreatic cancer and 68.8% in NSCLC [21][24] Summary by Sections Weekly New Drug Market Review - From September 15 to September 21, 2025, the top five gainers in the new drug sector included Kintor Pharmaceutical (+19.64%), Boan Biotechnology (+8.89%), and others, while the top five losers included Sanofi Pharmaceuticals (-17.16%) and others [1][13] Recommended Stocks to Watch - The report suggests focusing on several potential catalysts in the sector, including academic conferences and insurance negotiations. Key companies to watch include: 1. Differentiated GLP-1 assets: Zai Lab, EQRx, and others 2. Upgraded PD-1 products: CanSino Biologics and others 3. Companies likely to benefit from insurance negotiations: Hengrui Medicine, Kanghong Pharmaceutical, and others [2][17] New Drug Approval and Acceptance - This week, eight new drug applications were approved, and twelve new drug applications were accepted in China [3][25] Clinical Application Approvals - A total of 48 new drug clinical applications were approved, with 32 applications accepted this week [7][29]

Group 1 - The integration of AI and innovative pharmaceuticals is transforming the underlying logic of the pharmaceutical industry, potentially allowing China to achieve a "curve overtaking" in this field [1] - Traditional drug development has been characterized by high investment, high risk, and long cycles, with a success rate of only 10% after 10 years and 1 billion investment [1] - AI technology is expected to break the cycle of inefficiency in drug development by improving molecular design, identifying better targets, and shortening the time from development to patient use [1][2] Group 2 - The AI healthcare market is projected to grow at an annual rate of 43% from 2024 to 2032, with a market size expected to reach 3.58 trillion yuan, where drug discovery and medical imaging will account for over 50% of the market [3] - China's pharmaceutical companies, such as Heng Rui and Ji Tai Technology, are emerging as competitive players in AI drug development, with the AI pharmaceutical market expected to grow from 1.21 billion yuan in 2025 to 5.86 billion yuan by 2028, reflecting a compound annual growth rate of 68.3% [3] - The complete ecosystem and supply chain in China, along with a large number of CDMO companies, are contributing to the rapid growth of AI drug development [3][5] Group 3 - The "Implementation Plan for the Digital Transformation of the Pharmaceutical Industry (2025-2030)" has been released, aiming for comprehensive digital transformation of pharmaceutical enterprises by 2030 [4] - The combination of a complete supply chain, cross-disciplinary talent reserves, and policy incentives is driving the rapid development of AI pharmaceuticals in China [5] Group 4 - There is a growing trend of multinational pharmaceutical companies seeking to acquire Chinese innovative drugs, with the total value of License-out transactions nearing 66 billion USD in the first half of 2025 [6] - Significant collaborations have been established, such as the nearly 6 billion USD pipeline cooperation between Jing Tai Technology and DoveTree, and a 5.3 billion USD partnership between AstraZeneca and Shiyao Group [7] - The ultimate challenge for domestic AI pharmaceutical companies is to advance their research pipelines to commercialization, which will elevate them from "followers" to "leaders" in global innovation [7]

Core Insights - The integration of AI with innovative drug development is fundamentally transforming the pharmaceutical industry, presenting opportunities for China to potentially "overtake" in this field [1] Group 1: Efficiency Revolution - Traditional drug development has been characterized by high costs, risks, and long timelines, with a typical investment of 1 billion over 10 years yielding only a 10% success rate [1] - AI is expected to enhance molecular drug design, identify better targets, and shorten the timeline from development to patient use, as demonstrated by Novartis' application of AI throughout its drug development processes [1] Group 2: China's Natural Advantages - The AI healthcare market is projected to grow at an annual rate of 43% from 2024 to 2032, potentially reaching a market size of 3.58 trillion yuan, with drug discovery and medical imaging being the most prominent application areas [3] - China's pharmaceutical companies, such as Hengrui and various emerging firms, are increasingly developing AI drug discovery platforms, indicating a growing global competitiveness in AI-driven pharmaceuticals [3] - The AI pharmaceutical market in China is expected to expand from 1.21 billion yuan in 2025 to 5.86 billion yuan by 2028, with a compound annual growth rate of 68.3% [3] Group 3: Policy and Infrastructure Support - The "Implementation Plan for the Digital and Intelligent Transformation of the Pharmaceutical Industry (2025-2030)" aims for comprehensive digital transformation across large pharmaceutical enterprises by 2030 [4] - A robust supply chain, cross-disciplinary talent pool, and policy incentives are collectively driving the rapid development of AI pharmaceuticals in China [5] Group 4: Commercial Viability - The success of AI pharmaceutical companies hinges on their ability to establish a commercial closed loop, with significant licensing deals indicating strong interest from multinational companies in Chinese innovative drugs [6] - In 2025, the total value of licensing transactions for Chinese innovative drugs is projected to approach 66 billion USD, surpassing the total for 2024 [6] - Notable collaborations include a nearly 6 billion USD deal between Crystal Technology and DoveTree, and a partnership between AstraZeneca and CSPC for up to 5.3 billion USD [7] - The path to commercialization for domestic AI pharmaceutical companies is seen as a critical challenge, with the potential for these companies to transition from followers to leaders in global innovation [7]

Core Viewpoint - The Hong Kong Innovative Drug ETF (159567) has shown significant growth in both share volume and fund size since its inception, indicating strong investor interest in the innovative drug sector [1][2]. Fund Performance - As of September 18, 2024, the fund's share volume reached 8.17 billion shares, with a total size of 7.839 billion yuan, reflecting an increase of 1966.38% in share volume and 1974.81% in size compared to its initial figures on December 31, 2023 [1]. - The fund manager, Ma Jun, has achieved a return of 90.14% since taking over management on January 3, 2024 [2]. Trading Activity - The ETF recorded a trading volume of 12.58 billion yuan on September 19, 2024, with an average daily trading amount of 18.71 billion yuan over the last 20 trading days [1]. - Year-to-date, the ETF has accumulated a total trading amount of 206.404 billion yuan over 176 trading days, averaging 11.73 billion yuan per day [1]. Top Holdings - The ETF's major holdings include: - Innovent Biologics (9.52% holding, 263 million yuan market value) - WuXi Biologics (9.47% holding, 258 million yuan market value) - BeiGene (8.73% holding, 238 million yuan market value) - CanSino Biologics (7.62% holding, 208 million yuan market value) - China National Pharmaceutical Group (7.17% holding, 196 million yuan market value) [2].

Core Viewpoint - The company, 石药集团 (Stone Group), announced the grant of 9 million restricted shares to an employee under its restricted share award plan, pending acceptance by the recipient [1] Group 1 - The grant involves a total of 9 million restricted shares [1] - The recipient of the shares is an employee who is not a director, CEO, or a major shareholder, nor connected to any of these individuals [1] - The grant will only be effective upon acceptance by the recipient [1]

Group 1 - The company, CSPC Pharmaceutical Group (stock code: 01093), announced the grant of 9 million restricted shares to an employee under its restricted share award plan, pending acceptance by the grantee [1]

Group 1 - The company, Stone Pharmaceutical Group (01093.HK), announced the issuance of 9 million restricted shares as part of its restricted share award plan to an employee who is not a director, CEO, or a major shareholder [1] - The award is contingent upon the acceptance by the designated employee [1] - The announcement was made on September 19, 2025 [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產 生或因倚賴該等內容而引致之任何損失承擔任何責任。 CSPC PHARMACEUTICAL GROUP LIMITED 石 藥 集 團 有 限 公 司 （股份代號：1093） （於香港註冊成立之有限公司） 自願公告 根據本公司股份獎勵計劃授出股份獎勵 謹此 提述 石藥 集團 有限 公司（「本 公司」）於 2018 年8 月 20 日 刊發 有關 採納 本公 司限 制性 股份 獎勵計劃（「該計劃」）之公告（「該公告」）。誠如本公司日期為2024年5月21日之自願公告所披 露，該計劃之條款其後已作出修訂。除本公告另有界定外，本公告所用詞彙與該公告所界 定者具有相同涵義。 根據該計劃授出股份獎勵 董事會宣佈，於2025年9月19日，本公司根據該計劃向本集團的一名僱員（「承授人」）（ 其並 非 本 公 司 董 事 、 行 政 總 裁 或 主 要 股東 或 彼 等 任 何 人 士 之 聯 繫 人 士（ 定 義見 上 市 規 則 ））無 償 授 出 涉 及 合 共 ...